Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that researchers presented data from clinical trials supporting the chronic use of Soliris® (eculizumab) in a broad range of patients with atypical hemolytic uremic syndrome (aHUS), a genetic, chronic, ultra-rare disease associated with vital organ failure and premature death.

“The subgroup analyses from our large prospective trials provide additional support that Soliris is effective in a broad group of patients with aHUS, consistently showing that chronic treatment with Soliris inhibited systemic complement-mediated TMA, reversed renal damage, and decreased or eliminated the need for dialysis,” said Leonard Bell, M.D., Chief Executive Officer of Alexion … more